CU24716B1 - FORMA POLIMÓRFICA ESTABLE DE 6-FLUORO-9-METIL-9H-ß-CARBOLINA - Google Patents

FORMA POLIMÓRFICA ESTABLE DE 6-FLUORO-9-METIL-9H-ß-CARBOLINA

Info

Publication number
CU24716B1
CU24716B1 CU2022000008A CU20220008A CU24716B1 CU 24716 B1 CU24716 B1 CU 24716B1 CU 2022000008 A CU2022000008 A CU 2022000008A CU 20220008 A CU20220008 A CU 20220008A CU 24716 B1 CU24716 B1 CU 24716B1
Authority
CU
Cuba
Prior art keywords
carboline
fluoro
methyl
polymorphic form
stable polymorphic
Prior art date
Application number
CU2022000008A
Other languages
English (en)
Other versions
CU20220008A7 (es
Inventor
Hans Rommelspacher
Reimar Schlingensiepen
Tomasz Zygmunt
Original Assignee
Audiocure Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Audiocure Pharma Gmbh filed Critical Audiocure Pharma Gmbh
Publication of CU20220008A7 publication Critical patent/CU20220008A7/es
Publication of CU24716B1 publication Critical patent/CU24716B1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

<p>La presente invención se refiere a una forma polimórfica cristalina estable de 6-fluoro-9- metil-9H-β-carbolina de fórmula (I)</p> <p>Fórmula (l),</p> <p>así como un método para Ia preparación de dicha forma polimórfica cristalina de 6-fluoro-9-metil-9H-β-carbolina. Este compuesto se emplea en el tratamiento y/o profilaxis de daños auditivos, vértigo o trastornos vestibulares.</p>
CU2022000008A 2019-08-09 2020-08-07 FORMA POLIMÓRFICA ESTABLE DE 6-FLUORO-9-METIL-9H-ß-CARBOLINA CU24716B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19191150.2A EP3772515A1 (en) 2019-08-09 2019-08-09 Stable polymorphic form of 6-fluoro-9-methyl-9h-ss-carboline and uses thereof
PCT/EP2020/072328 WO2021028365A1 (en) 2019-08-09 2020-08-07 Stable polymorphic form of 6-fluoro-9-methyl-9h-b-carboline and uses thereof

Publications (2)

Publication Number Publication Date
CU20220008A7 CU20220008A7 (es) 2022-09-08
CU24716B1 true CU24716B1 (es) 2024-07-10

Family

ID=67614427

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2022000008A CU24716B1 (es) 2019-08-09 2020-08-07 FORMA POLIMÓRFICA ESTABLE DE 6-FLUORO-9-METIL-9H-ß-CARBOLINA

Country Status (18)

Country Link
US (1) US12466824B2 (es)
EP (2) EP3772515A1 (es)
JP (1) JP7337254B2 (es)
CN (1) CN114269743B (es)
AU (1) AU2020329535B2 (es)
BR (1) BR112022001433A2 (es)
CA (1) CA3143605A1 (es)
CL (1) CL2022000225A1 (es)
CU (1) CU24716B1 (es)
DK (1) DK3972974T3 (es)
ES (1) ES3003258T3 (es)
IL (1) IL290272A (es)
MX (1) MX2022001566A (es)
MY (1) MY206963A (es)
PH (1) PH12021553191A1 (es)
PL (1) PL3972974T3 (es)
WO (1) WO2021028365A1 (es)
ZA (1) ZA202201719B (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040038970A1 (en) 1998-06-12 2004-02-26 Societe De Conseils De Recherches Etd' Application Scientifiques, S.A.S. A Paris, France Corp. Beta-carboline compounds
DE102007009264A1 (de) 2007-02-26 2008-08-28 Ellneuroxx Ltd. 9-Alkyl-ß-Carboline zur Behandlung von neurodegenerativen Erkrankungen
EP2519238B1 (de) * 2009-12-28 2014-08-13 Audiocure Pharma GmbH Beta-carboline zur behandlung von hörschäden und schwindel
EP2853533A1 (de) * 2013-09-29 2015-04-01 Audiocure Pharma GmbH 6-Fluor-9-methyl-ß-carbolin

Also Published As

Publication number Publication date
JP2022545361A (ja) 2022-10-27
IL290272A (en) 2022-04-01
AU2020329535A1 (en) 2022-01-20
ES3003258T3 (en) 2025-03-10
WO2021028365A1 (en) 2021-02-18
EP3972974B1 (en) 2024-10-23
AU2020329535B2 (en) 2025-06-26
CN114269743A (zh) 2022-04-01
PL3972974T3 (pl) 2025-03-10
CN114269743B (zh) 2023-11-10
US12466824B2 (en) 2025-11-11
PH12021553191A1 (en) 2022-10-24
US20220289741A1 (en) 2022-09-15
EP3972974A1 (en) 2022-03-30
MY206963A (en) 2025-01-22
JP7337254B2 (ja) 2023-09-01
EP3772515A1 (en) 2021-02-10
CA3143605A1 (en) 2021-02-18
BR112022001433A2 (pt) 2022-03-22
ZA202201719B (en) 2023-11-29
CU20220008A7 (es) 2022-09-08
CL2022000225A1 (es) 2022-09-09
MX2022001566A (es) 2022-03-02
DK3972974T3 (da) 2024-11-25

Similar Documents

Publication Publication Date Title
PH12015502443A1 (en) 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
MX379474B (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales
MX374296B (es) Compuestos de pirazina novedosos para el tratamiento de enfermedades infecciosas
MX2020007265A (es) Derivados de rapamicina.
ECSP15018618A (es) Inhibidores no nucleósidos de la transcriptasa inversa
PH12019500432B1 (en) 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection
MX2021005052A (es) Oxiesteroles y métodos de uso de los mismos.
ECSP17026210A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos
CR20140231A (es) Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih
UY35617A (es) Inhibidores de la fosfatidilinositol 3-quinasa
UY35242A (es) Inhibidores de fosfatidilinositol 3-quinasa
EA201690669A1 (ru) Замещенные производные хинолизина, которые можно использовать как ингибиторы интегразы вич
CO6541569A2 (es) Inhibidores de n1-pirazoloespirocetona acetil-coa carboxilasa
CR20120503A (es) Inhibidores no nucleosídicos de la transcriptasa inversa
PH12019501198A1 (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
MX2018008095A (es) Compuestos heterociclicos triciclicos condensados como inhibidores de integrasa del vih.
UY34027A (es) Inhibidores sustituidos de acetil-coa carboxilasa.
UY35381A (es) Pirrolotriazinas como inhibidores del canal del ion potasio
EA201100750A1 (ru) Замещенные диоксопиперидинилфталимидные производные
MX370933B (es) Inhibidores jak.
UY37774A (es) Compuestos 5-cianoindol sustituidos y usos de los mismos
MY182353A (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
CO2021000932A2 (es) Forma cristalina de compuesto profármaco de lanosterol y aplicación de la misma
MD20190080A2 (ro) Forme cristaline de (s)-afoxolaner
CL2020003248A1 (es) Derivados de tetrahidrotienopiridina n-sustituidos y sus usos